Abstract Library

#4587 Exploring the splicing landscape to identify survival-related biomarkers in small intestine neuroendocrine neoplasms

Introduction: The study of small intestine neuroendocrine neoplasms (siNENs) is challenging due to their rarity and complexity. While transcriptomic subtypes have been identified, the mechanisms behind their progression are still unclear. The process of RNA splicing is often altered in cancer, and our group has described that such dysregulation is also present in various NENs.

Conference:

Presenting Author: Ibáñez Costa A

Authors: Ibáñez-Costa A, García Vioque V, Pedraza-Arévalo S, Hernando Cubero J, García A,

Keywords: small intestine neuroendocrine tumour, splicing, biomarker, survival, ki-67, RNA,

#4199 Unravelling the RNA landscape of small intestine neuroendocrine neoplasms applying transcriptomic and spliceosomic perspectives

Introduction: The study of small intestine neuroendocrine neoplasms (siNENs) transcriptomics represents a challenge due to their rarity, tissue availability, and heterogeneity. Recent studies identified different molecular subtypes, but there are still gaps in the molecular mechanisms driving siNEN progression.

Conference:

Presenting Author:

Authors: Ibáñez-Costa A, Pedraza-Arevalo S, Moreno-Montilla M, Hernando J, García A,

Keywords: small intestine neuroendocrine neoplasm, splicing, transcriptomics, biomarker,

#3847 RNA m6A methylation regulators in lung neuroendocrine neoplasms

Introduction: Lung carcinoids are commonly slow-proliferating neuroendocrine neoplasms (LungNENs) with a low mutational burden. Recent research has suggested a severe alteration in the profile of alternative splicing in LungNENs. In contrast, the role of emerging related systems like the genes regulating N6 methyladenosine (m6A), the most abundant internal modification of RNA, has been poorly explored in these rare tumors. We hypothesize that the expression profile of m6A-related genes could be altered in LungNENs in relation to their development.

Conference:

Presenting Author:

Authors: Ibáñez-Costa A, García Vioque V, Blázquez-Encinas R, Moreno Montilla M, Pedraza-Arévalo S,

Keywords: carcinoid, neuroendocrine tumor, lung, m6a, RNA, methylation,

#3512 Genetic, epigenetic and/or transcriptional profiling of 14q genes, MAX and MEG3 in pituitary neuroendocrine tumors

Introduction: Recent studies have identified a growing series of susceptibility genes for pituitary neuroendocrine tumors (PitNETs) and pheochromocytomas/paragangliomas (PPGL). Some of these genes (e.g., SDH genes) have be specifically associated with the development of these pathologies.

Conference:

Presenting Author: Ibáñez Costa A

Authors: Ibáñez-Costa A, Letón R, Rivero-Cortés E, Álvarez-Escolá C, Rodriguez Poyo-Guerrero P,

Keywords: pituitary tumor, epigenetics, MAX, genomics,

#3257 Molecular and functional study of somatostatin receptors in pheochromocytomas and paragangliomas

Introduction: Most pheochromocytomas (PCC) and paragangliomas (PGL) are benign neuroendocrine tumors that overproduce catecholamines causing hypertension, arrhythmia, and stroke; however, 10 30% may present distant metastasis. About 40% are caused by germline mutations, which may be classified in 3 different clusters. PCC/PGL diagnosis involves blood/urine tests and imaging techniques, while their treatment often requires distinct pharmacological and surgical approaches. Thus, identification of new biomarkers for early diagnosis, and progression/response would help to avoid unnecessary tests and enable personalized medicine approaches.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ibáñez-Costa A

Authors: Ibáñez-Costa A, Blázquez-Encinas R, Alors-Pérez E, Fuentes-Fayos A, Rivero-Cortés E,

Keywords: pheochromocytoma, paraganglioma, somatostatin, somatostatin receptor, neuroendocrine tumor,